SCHEMBL6335286

SCHEMBL6335286

O=C(c1cc(Br)c(O)c(Br)c1)c1c(Cc2ccccc2)sc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 11/20 0.60
▸ CYP2C19 P33261 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ TTR P02766 2/20 0.44
▸ EYA3 Q99504 2/20 0.44
▸ EYA2 O00167 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ ABCC4 O15439 1/20 0.44
▸ PLIN1 O60240 1/20 0.44
▸ NR1I2 O75469 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ ABCB11 O95342 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ ALB P02768 1/20 0.44
▸ ESR1 P03372 1/20 0.44
▸ NR3C1 P04150 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ PGR P06401 1/20 0.44
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6335387 0.84 PTPN1 (0.68) PTPN1NR1H4
SCHEMBL13799834 0.82 PTPN1 (0.57) PTPN1NR1H4CNR2
SCHEMBL6344128 0.82 PTPN1 (0.53) PTPN1MEN1LMNAESR1MAPT
SCHEMBL6343805 0.81 PTPN1 (0.52) PTPN1NR1H4CNR2
SCHEMBL7497867 0.75 PTPN1 (1.00) PTPN1
SCHEMBL6337585 0.75 CNR2 (0.75) PTPN1MEN1ALDH1A1LMNAESR1
SCHEMBL7816703 0.75 CNR2 (0.57) PTPN1ALDH1A1CNR2
SCHEMBL7816066 0.75 CNR2 (0.54) PTPN1CYP2C19CYP2C9ALDH1A1LMNA
SCHEMBL7816077 0.75 CNR2 (0.51) PTPN1MEN1ALDH1A1LMNAPOLB
SCHEMBL6336499 0.72 EYA3 (0.73) PTPN1CYP2C19CYP2C9TTREYA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102480-A1 Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2004-05-27 — — US claimed
EP-1077965-A1 PHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 — — EP claimed
WO-1999058519-A1 PHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 — — WO claimed
US-6844358-B2 Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2005-01-18 — — US disclosed
US-20040102480-A1 Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2004-05-27 — — US disclosed
US-6509360-B1 a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. WYETH 2003-01-21 — — US disclosed
EP-1077965-A1 PHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 — — EP disclosed
US-6166069-A Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION (US) 2000-12-26 — — US disclosed
WO-1999058519-A1 PHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102480-A1 Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, GCKR PTPN1 1600/4885CYP2C19 906/4885CYP2C9 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback